Chemometec A/S
CSE:CHEMM

Watchlist Manager
Chemometec A/S Logo
Chemometec A/S
CSE:CHEMM
Watchlist
Price: 487.6 DKK -0.69% Market Closed
Market Cap: 8.5B DKK
Have any thoughts about
Chemometec A/S?
Write Note

Net Margin
Chemometec A/S

33.4%
Current
36%
Average
0.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
33.4%
=
Net Income
136.3m
/
Revenue
407.9m

Net Margin Across Competitors

Country DK
Market Cap 8.5B DKK
Net Margin
33%
Country US
Market Cap 1.2T USD
Net Margin
9%
Country US
Market Cap 202.3B USD
Net Margin
14%
Country US
Market Cap 166.6B USD
Net Margin
18%
Country KR
Market Cap 66.8T KRW
Net Margin
24%
Country CH
Market Cap 38.4B CHF
Net Margin
9%
Country US
Market Cap 38.8B USD
Net Margin
20%
Country US
Market Cap 36.3B USD
Net Margin
9%
Country US
Market Cap 27B USD
Net Margin
21%
Country US
Market Cap 24.1B USD
Net Margin
17%
Country CN
Market Cap 164.6B CNY
Net Margin
21%
No Stocks Found

Chemometec A/S
Glance View

Market Cap
8.5B DKK
Industry
Life Sciences Tools & Services

Chemometec A/S, a Danish firm founded in the late 1990s, has carved a niche in the specialized world of biotech instrumentation. The company is renowned for developing and manufacturing high-precision cell counting and analysis instruments used predominantly in the life sciences sector. Its flagship product, the NucleoCounter®, has gained significant traction in laboratories and production facilities worldwide. This product stands out due to its accuracy and ease of use in counting various types of cells, whether in research or pharmaceutical production settings. Unlike traditional methods, Chemometec’s technology enables researchers to save time and reduce error, which is invaluable for laboratories looking to enhance their workflow efficiencies. Revenue for Chemometec is primarily generated through the sale of its advanced instruments and associated consumables, along with providing expert services that support the integration and maintenance of these technologies. The company's business model capitalizes on the growing global demand for sophisticated biomedical research tools, as innovation in the drug development and biotechnology sectors accelerates. By continuously investing in R&D, Chemometec not only ensures its products remain cutting-edge but also expands its applicability across new areas in the life sciences field. The strategy of maintaining close relationships with its end-users ensures that as the scientific landscape evolves, Chemometec is well-positioned to adapt and grow.

CHEMM Intrinsic Value
324.51 DKK
Overvaluation 33%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
33.4%
=
Net Income
136.3m
/
Revenue
407.9m
What is the Net Margin of Chemometec A/S?

Based on Chemometec A/S's most recent financial statements, the company has Net Margin of 33.4%.